Aberdeen Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Aberdeen Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$5.67M	Sell	43,975 -3,444	-7%	-$415K	0.02%	444
2017 Q1	$5.19M	Buy	47,419 +4,030	+9%	+$355K	0.02%	450
2016 Q4	$3.2M	Sell	43,389 -3,173	-7%	-$258K	0.01%	504
2016 Q3	$4.06M	Sell	46,562 -160	-0.3%	-$15.1K	0.01%	466
2016 Q2	$4.02M	Sell	46,722 -465	-1%	-$40.2K	0.01%	451
2016 Q1	$3.75M	Sell	47,187 -4,881	-9%	-$442K	0.01%	468
2015 Q4	$5.7M	Buy	52,068 +8,513	+20%	+$1.03M	0.02%	397
2015 Q3	$4.54M	Sell	43,555 -2,286	-5%	-$294K	0.02%	390
2015 Q2	$5.66M	Sell	45,841 -890	-2%	-$112K	0.02%	369
2015 Q1	$5.51M	Sell	46,731 -5,601	-11%	-$671K	0.01%	367
2014 Q4	$6.22M	Sell	52,332 -13,809	-21%	-$1.56M	0.02%	342
2014 Q3	$7.43M	Sell	66,141 -7,946	-11%	-$757K	0.02%	356
2014 Q2	$7.01M	Buy	74,087 +49,587	+202%	+$3.48M	0.01%	390
2014 Q1	$1.73M	Buy	24,500 +1,300	+6%	+$103K	﹤0.01%	363
2013 Q4	$1.71M	Hold	23,200	–	–	﹤0.01%	336
2013 Q3	$1.76M	Buy	+23,200	New	+$1.85M	0.01%	320

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Aberdeen Asset Management's VRTX Position: Q2 2017 in Review

Aberdeen Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2017, selling an estimated $415K and leaving 43,975 shares worth $5.67M. The position accounts for 0.02% of the portfolio, ranked #444.

Aberdeen Asset Management first reported a position in VRTX in Q3 2013 and has held it in 16 quarters since. The position peaked at $7.43M in Q3 2014. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Aberdeen Asset Management held 43,975 shares of Vertex Pharmaceuticals worth $5.67M as of Q2 2017.
Aberdeen Asset Management sold 3,444 Vertex Pharmaceuticals shares in Q2 2017, an estimated $415K.
Vertex Pharmaceuticals made up 0.02% of Aberdeen Asset Management's portfolio in Q2 2017, its #444 holding.
Aberdeen Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 16 quarters since.
Aberdeen Asset Management's Vertex Pharmaceuticals position peaked at $7.43M in Q3 2014.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.